Post Archive by Month

Sexually transmitted infections (STIs) are increasingly spreading across Europe during the summer of 2025.
Every day, approximately one million people worldwide contract an STI.
The European Centre for Disease Prevention and Control (ECDC) has recently urged individuals at risk to stay informed about available vaccine options. In addition to chlamydia and syphilis, vaccines are available for gonorrhea, HPV, and mpox.

The United States could safely reduce the frequency of tetanus and diphtheria booster shots for adults and save an estimated $1 billion per year, according to a new review led by researchers at Oregon Health & Science University.
This conclusion depends on the U.S. maintaining very high childhood vaccination rates.
Vaccines for tetanus and diphtheria are referred to as “legacy” vaccines by the healthcare industry because they were developed in the 1920s, during a time when the U.S. Food and Drug Administration was in its early stages of development.

The Chikungunya virus, transmitted by mosquitoes, has emerged as a significant global health concern. Recent outbreaks have spread beyond their usual regions in Africa and Asia to areas such as the Region of the Americas, China, France, and India.
Although the acute febrile illness typically resolves within a few days, many patients experience prolonged joint pain and arthritis.
This can severely impact their quality of life and place a burden on healthcare resources.

As parents prepare to send their children back to school in August 2025, many are concerned about the under-vaccination rate in their country.
According to the Pan American Health Organization (PAHO), 1.4 million children in the Americas did not receive a single dose of the diphtheria, tetanus, and pertussis (DTP)-containing vaccine, marking an increase in so-called “zero-dose” children.

Over many decades, vaccine-preventable disease outbreaks have occurred in low- and middle-income countries, necessitating emergency response immunization programs to save lives and reduce the costs associated with these outbreaks.
Estimates from the Global Burden of Disease indicate that between 2015 and 2019, around two million deaths per year were attributable to vaccine-preventable diseases.

With the acceleration of Chikungunya outbreaks being reported in Europe during the spring of 2025, older Europeans now have two approved vaccines to choose from before visiting an at-risk area this summer.
As of July 11, 2025, Valneva SE announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva's single-dose Chikungunya vaccine IXCHIQ® by the EMA's safety committee.